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Substance-related disordersBuprenorphine abuse is common worldwide. Rates of abuse and diversion of three sublingual buprenorphine
formulations (single ingredient tablets; naloxone combination tablets and ﬁlm) were compared. Data were
obtained from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System
Poison Center, Drug Diversion, Opioid Treatment (OTP), Survey of Key Informants' Patients (SKIP), and
College Survey Programs through December 2012. To control for drug availability, event ratios (rates) were
calculated quarterly, based on the number of patients ﬁlling prescriptions for each formulation (“unique
recipients of a dispensed drug,” URDD) and averaged and compared using negative binomial regression.
Abuse rates in the OTP, SKIP, and College Survey Programs were greatest for single ingredient tablets, and
abuse rates in the Poison Center Program and illicit diversion rates were greatest for the combination tablets.
Combination ﬁlm rates were signiﬁcantly less than rates for either tablet formulation in all programs. No
geographic pattern could be discerned.
© 2014 The Authors. Published by Elsevier Company. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Buprenorphine sublingual formulations are approved in the
United States (US) for the treatment of opioid dependence (FDA,
2002). Buprenorphine therapy improves retention in substance abuse
treatment, decreases emergency department utilization and high-risk
sexual behaviors, and improves overall quality of life (Maremmani,
Pani, Pacini, & Perugi, 2007; Schwarz, Zelenev, Bruce, & Altice, 2012;
Sullivan et al., 2008). Buprenorphine is a long-acting partial agonist of
the μ-opioid receptor, a full κ-receptor antagonist, and an ORL-1nited States Food and Drug
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ompany. This is an open access articpartial agonist (Walsh, Preston, Stitzer, Cone, & Bigelow, 1994).
Buprenorphine exhibits a ceiling agonist effect at high doses, and
because of its high afﬁnity for the μ-receptor buprenorphine can
interfere with the binding of pure μ-agonists, such as morphine.
Because of this, concurrent use of buprenorphine blocks the “high”
ordinarily received from abuse of high-potency opioid agonists, such
as hydromorphone, and early studies suggested that abuse liability
was low by the sublingual route (Walsh & Eissenberg, 2003).
Sublingual buprenorphine is available in the US in three
formulations. The single ingredient and naloxone combination tablet
formulations were introduced in the US in January 2003, and a
mucoadhesive combination ﬁlm formulation was introduced in
September 2010. In the combination tablets and ﬁlm, naloxone is
incorporated in a ﬁxed ratio (1 mg naloxone per 4 mg buprenor-
phine) to deter abuse by parenteral routes, such as nasal insufﬂation
(“snorting”) or injection (Fudala & Johnson, 2006; Mendelson & Jones,
2003). Although use for off-label indications has been described, the
most common and only approved use of buprenorphine sublingual
formulations in the US is for ofﬁce-based treatment of opioid
dependence, an indication for which its overall safety and effective-
ness has been established (Amass et al., 2004; Fiellin & O'Connor,
2002; Johnson, Jaffe, & Fudala, 1992; Mattick, Kimber, Breen, & Davoli,
2008). In the ﬁnal quarter of 2012, approximately 750,000 patientsle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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unpublished data). Generic formulations of single ingredient bupre-
norphine tablets have been available in the US since late 2009, and
combination tablets since February 2013.
Data from several US sources demonstrate that buprenorphine
sublingual formulations are diverted and utilized outside of an
established physician–patient relationship, both for self-medication
of withdrawal symptoms and to produce euphoria (Daniulaityte,
Falck, & Carlson, 2012; Yokell, Zaller, Green, & Rich, 2011). To date,
few studies have directly compared abuse and diversion rates of
buprenorphine single ingredient and combination tablet formula-
tions, and abuse and diversion rates for the combination ﬁlm have not
been reported (Comer & Collins, 2002; Dasgupta et al., 2010;
Johanson, Arfken, di Menza, & Schuster, 2012).
The purpose of this study was to measure and compare rates of
diversion and abuse of the three formulations of sublingual bupre-
norphine available in the US.2. Materials and methods
2.1. Data source
Data were obtained from ﬁve programs of the Researched Abuse,
Diversion, and Addiction-Related Surveillance (RADARS®) System, as
described below. Methods of the RADARS System and its component
programs have been described previously (Inciardi et al., 2009). In all
RADARS System Programs, data about substance abuse and diversion
are collected to the level of the speciﬁc formulation andmanufacturer,
including generic manufacturers, and rates are calculated quarterly.2.1.1. Poison Center Program
The RADARS System Poison Center Program measures reports to
poison centers involving people exposed to prescription opioid and
stimulant medications. Fifty of the 57 poison centers operating in the
US during the study period participated in the Poison Center Program,
and 90.2 percent of the US population (excluding residents of
Puerto Rico) resided in a covered area. Calls are initiated to poison
centers by health care professionals or the general public, generally
because of an acute medical event. Certiﬁed specialists in poison
information collect data using narrative case notes and standardized
data ﬁelds with deﬁnitions established by the American Association of
Poison Control Centers (AAPCC, 2007). De-identiﬁed case-level data
are transmitted to the RADARS System Poison Center Program, where
research staff perform data integrity checks using standardized
methods (Winter et al., 2012), and feedback is provided to improve
data accuracy (Winter et al., 2013). The RADARS System Poison Center
Program began collecting buprenorphine data in October, 2010.
For this analysis, only calls for which the reason for exposure was
intentional abuse (“an exposure resulting from the intentional
improper or incorrect use of a substance where the victim was likely
attempting to gain a high, euphoric effect, or some other psychotropic
effect”) were included. A secondary analysis was performed on a
subset of these patients for whom the route of exposure was
“parenteral” (deﬁned as, “an exposure resulting from the injection
of a substance into the body”) or “inhalation/nasal.”2.1.2. Drug Diversion Program
The RADARS System Drug Diversion Program measures illicit
diversion by collecting reports of new police investigations, such as
forged prescriptions, street drug “buys,” and pharmacy robberies,
from law enforcement agencies. Approximately 260 police agencies in
49 states and the District of Columbia participate in the Drug
Diversion Program. The RADARS System Drug Diversion Program
began collecting buprenorphine data in October, 2010.2.1.3. Treatment programs (Opioid Treatment Program and Survey of
Key Informants' Patients Programs)
In the RADARS System Opioid Treatment Program (OTP) and
Survey of Key Informants' Patients Program (SKIP), patients entering
substance abuse treatment who choose to participate complete a 2-
page survey about their substance abuse history. Abuse events are
captured by asking subjects to report all opioid medications, “Used in
[the] past month to get high.” Patients participating in the OTP and
SKIP programs are predominately white (56%) male (52%) young
adults (median age 31 years (interquartile range: 26–39 years)).
During the study period, 83–86 percent of eligible patients chose to
participate in the SKIP and 90–95 percent of eligible patients in the
OTP. Approximately 79 federally certiﬁed treatment programs in 34
states participate in the OTP, and 125 treatment practices in 50 states
participate in the SKIP. Data from the OTP and SKIP programs were
combined for this analysis.
The primary analysis was performed on all abuse endorsements, and
a secondary analysis was performed limiting data to cases in which the
patient endorsed buprenorphine abuse by injection. The treatment
programs began collecting buprenorphine data in April 2011.
2.1.4. College Survey Program
The RADARS System College Survey Program is an online question-
naire collectingdata fromself-identiﬁed students attending a2- or 4-year
college, university or technical school at least part-time during the
speciﬁed sampling period. Data from approximately 2,000 participants
are collected at the completion of the fall and spring academic semesters/
quarters andat the endof the summer. Each sample is equally distributed
across the four geographic regions of the United States (W, NW, S, and
NE) and is composed of self-identiﬁed students who have agreed to be
contacted to complete online surveys. Cases are deﬁned as self-reported
non-medical use of prescription opioid or stimulant medication by
college students in the previous academic semester/quarter or over the
summer break. Although non-medical use is not strictly synonymous
with abuse (for example, using a roommate's oxycodone to treat pain
from a sports injury is non-medical use but not abuse), in the vernacular
of this report the terms are used interchangeably. Cases are assigned to
the reported 3-digit ZIP code of the college student's residence. The
College Survey Program began collecting buprenorphine data with the
spring term 2011 survey.
2.2. Rate calculations
In order to account for differences in the availability of different drug
formulations in the community, event ratios (rates) were calculated
based on the number of personsﬁlling prescriptions (“unique recipients
of a dispensed drug,” URDD). One URDD is a single person ﬁlling a
prescription for a speciﬁc product in a 3-digit zip code area covered by a
RADARS System program in a year-quarter. Sales data used to calculate
URDD were purchased from IMS Health Solutions (Parsippany, NJ). A
complete description of URDD and themethod bywhich URDD data are
used to calculate rates have been published previously (Dasgupta et al.,
2010; Smith et al., 2007). In order to provide context about changing
prescribing of the three buprenorphine formulations over the study
period, national-level URDD data were compared with population data
from the US Census Bureau, using linear interpolation to produce
quarterly data between available population data points.
Program event rates for each of the three formulations were
calculated quarterly, and the averages of these rates, calculated using
negative binomial regression, were used for the primary analysis. For
each RADARS System program, the time period for analysis began
during the ﬁrst year/quarter for which buprenorphine data were
collected and ended in the ﬁnal quarter of 2012. Thus, the primary
analysis contains 27 months of data in the Poison Center and Drug
Diversion Programs, 21 months of data in the treatment programs,
and 6 terms of data (approximately 18 months of sampling period
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Fig. 1. Prescribing trends of buprenorphine sublingual formulations, United States
October 2010–December 2012. URDD: unique recipients of a dispensed drug. Data from
IMS Global Health and US Census Bureau.
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between the three formulations were made using negative binomial
regression, and a two-tailed alpha level of 0.05 was used to deﬁne
statistical signiﬁcance. Data from the treatment programs were
combined for the primary analysis, and OTP and SKIP data were
reported separately in secondary analyses.
2.3. Geographic analysis
In an exploratory analysis, we examined state-level data about
abuse and diversion of the three buprenorphine formulations. Maps
were generated to show which formulation had the highest average
abuse and diversion rates during the study period for each program, as
deﬁned above. Results were presented graphically; statistical com-
parisons were not performed on state-level data.
2.4. Human subjects protection
Overall operation of the RADARS System and of the Poison Center
and College Survey Programs is approved by the Colorado Multiple
Institution Institutional Review Board (IRB). In the Poison Center
Program, the local IRB for each participating poison center also
provides oversight for that center's participation. Operation of the
Drug Diversion Program has been reviewed and classiﬁed as exempt
by the Nova Southeastern University IRB. Operation of the OTP is
approved by the National Development and Research Institutes IRB,
and SKIP is approved by the Washington University IRB. Participants
in the OTP, SKIP, and College Survey programs provided informed
consent. Drug Diversion Program data are submitted by law
enforcement personnel reporting about criminal investigations and
do not involve any patient or arrestee data, and waiver of informed
consent has been approved for all centers participating in the Poison
Center Program. All study procedures were performed in accord with
US FDA regulations and the Helsinki Declaration of 1975. No protected
health information is transmitted between sites.
3. Results
3.1. Changes in prescribing over time
Between October 2010 and December 2012, the number of
patients ﬁlling prescriptions for sublingual buprenorphine formula-
tions increased faster than the US population as a whole, but the
change was not similar over the three formulations (Fig. 1). The
increase was greatest for combination ﬁlm (228% increase relative to
population). The number of patients ﬁlling prescriptions for single
ingredient tablets increased 66% relative to population during the
same period, while there was a 58% decrease in the number of patient
ﬁlling prescriptions for combination tablets.
3.2. Poison center intentional-abuse cases involving buprenorphine
A total of 1,068 reports of intentional abuse of buprenorphine was
received by the Poison Center Program over the 27-month study
period. Adjusting for the number of patients ﬁlling prescriptions for
each formulation (URDD), the average abuse rate for single ingredient
tablets was 1.6 times that of combination ﬁlm, and the average abuse
rate for combination tablets was approximately 4 times that of the
combination ﬁlm (Table 1). These relationships were consistent over
time (Fig. 2).
3.3. Drug diversion cases involving buprenorphine
A total of 1,374 cases of buprenorphine diversion was reported to
the Drug Diversion Program over the 27-month study period.
Adjusting for the number of patients ﬁlling prescriptions (URDD),,there were 6.4 times as many drug diversion cases involving single
ingredient tablets and approximately 11 times as many cases
involving combination ingredient tablets as cases involving the
combination ﬁlm (Table 1). These differences were statistically
signiﬁcant, and the relationships were consistent for all year-quarters
studied (Fig. 2).
3.4. Reports of buprenorphine abuse by patients entering treatment
Overall, 4,669 patients (37.8% of all OTP and SKIP program
participants) endorsed recent (past-month) buprenorphine abuse
during the 21-month study period. Separate review of results from the
OTP and SKIP showed no signiﬁcant differences that would preclude
combining data from the treatment programs for analysis (Supple-
mental Table A1 – on-line only).
In the treatment programs, availability-adjusted abuse rates for
the single ingredient tablets exceeded those for the combination
tablets or the combination ﬁlm (Table 1). The abuse rate for the single
ingredient tablets was 6.5 times that of combination ﬁlm, while the
combination tablet abuse rate was twice the combination ﬁlm rate.
The differences were statistically signiﬁcant and consistent over
time (Fig. 2).
3.5. Abuse among college students
A total of 183 students endorsed non-medical use of buprenor-
phine sublingual formulations. After adjusting for availability (URDD)
in the students' home communities, average abuse rates for single
ingredient tablets were 11 times the abuse rate for combination ﬁlm,
and the combination tablet abuse rate was 2.2 times the combination
ﬁlm rate (Table 1). These relationships are statistically signiﬁcant and
have been stable over the 6 terms of the study period (Fig. 2).
3.6. Abuse by non-oral routes
The Poison Center Program contained 229 reports of abuse by
injection or snorting during the study period (21.4% of all abuse
Table 1
Average rates of abuse and diversion of three sublingual buprenorphine formulations, adjusted for drug availability, in the RADARS® System.
Rate (program events
per 10,000 URDD)
95% Conﬁdence
interval
Rate ratio compared with
combination ﬁlm
95%
Conﬁdence
interval
Signiﬁcance
Poison Center Program
Buprenorphine tablets 1.5 1.2 1.9 1.6 1.1 2.4 p = 0.009
Buprenorphine/naloxone tablets 3.7 3.4 4.0 4.1 3.0 5.7 p b 0.001
Buprenorphine/naloxone ﬁlm 0.9 0.8 1.1 Reference
Drug Diversion Program
Buprenorphine tablets 8.5 7.4 9.7 6.4 4.2 9.7 p b 0.001
Buprenorphine/naloxone tablets 13.1 12.3 14.0 10.9 7.3 16.4 p b 0.001
Buprenorphine/naloxone ﬁlm 1.4 1.2 1.6 Reference
Combined treatment programs (OTP + SKIP)
Buprenorphine tablets 62.4 59.4 65.5 6.5 5.3 7.9 p b 0.001
Buprenorphine/naloxone tablets 20.8 19.8 21.9 2.2 1.8 2.7 p b 0.001
Buprenorphine/naloxone ﬁlm 9.5 9.0 10.1 Reference
College Survey Program
Buprenorphine tablets 2.3 1.8 2.8 11.1 7.4 16.6 p b 0.001
Buprenorphine/naloxone tablets 0.4 0.3 0.6 2.2 1.4 3.4 p b 0.001
Buprenorphine/naloxone ﬁlm 0.2 0.1 0.3 Reference
URDD: unique recipients of a dispensed drug; OTP: Opioid Treatment Program; SKIP: Survey of Key Informants' Patients Program.
Analytic period: Poison Center and Drug Diversion Programs, October 2010–December 2012; treatment programs, April 2011–December 2012; College Survey Program, spring term
2011–fall term 2012.
Poison Center Program data are limited to intentional abuse exposures. Abuse reports in the treatment programs refer to use “to get high” in the past month. Abuse reports in
the College Survey Program refer to non-medical use in the past semester. Diversion reports in the Drug Diversion Program are law enforcement investigations initiated in
the year/quarter.
Buprenorphine single ingredient tablets
Buprenorphine / naloxone combination tablets
Buprenorphine / naloxone combination film
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Fig. 2. Average rates of abuse and diversion of three sublingual buprenorphine formulations, adjusted for drug availability, in the RADARS® System. URDD: unique recipients of a
dispensed drug.
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Table 2
Average rates of abuse by non-oral routes of three buprenorphine sublingual formulations, adjusted for drug availability, in the RADARS® System Poison Center Program and
combined treatment programs.
Rate (abuse reports
per 10,000 URDD)
95% Conﬁdence
interval
Rate ratio compared with
combination ﬁlm
95% Conﬁdence
interval
Signiﬁcance
Poison Center Program: Parenteral + nasal routes only
Buprenorphine tablets 0.6 0.4 0.8 3.5 2.1 5.8 p b 0.001
Buprenorphine/naloxone tablets 0.8 0.6 0.9 4.8 3.2 7.2 p b 0.001
Buprenorphine/naloxone ﬁlm 0.2 0.1 0.2 Reference
Combined treatment programs: Injection use only
Buprenorphine tablets 27.0 25.1 29.1 20.0 15.4 25.6 p b 0.001
Buprenorphine/naloxone tablets 3.3 2.9 3.7 2.5 1.9 3.3 p b 0.001
Buprenorphine/naloxone ﬁlm 1.3 1.2 1.6 Reference
URDD: unique recipients of a dispensed drug.
Poison Center Program data are limited to intentional abuse exposures for which the reason for exposure is “parenteral” (injection) or “inhalation/nasal.” Treatment program
data combine data from the RADARS System Opioid Treatment and Survey of Key Informants' Patients Programs, with analysis limited to injection use exposures “to get high” in
the past month.
Analytic period: Poison Center and Drug Diversion Programs, October 2010–December 2012; treatment programs, April 2011–December 2012; College Survey Program, spring term
2011–fall term 2012.
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rates were seen with the combination tablets, and the lowest abuse
rates were seen with the combination ﬁlm.
A total of 1,186 patients reported injecting a buprenorphine
sublingual formulation “to get high” in the 30 days prior to entering
the treatment programs (Table 2). This number represents 25.4% of all
buprenorphine sublingual formulation abuse endorsements. The
availability-adjusted injection abuse rate for single ingredient
buprenorphine tablets was 20 times the injection abuse rate for the
combination ﬁlm, and combination tablet injection was reported at a
supply-adjusted rate 2.5 times that of combination ﬁlm.
3.7. Geographic analysis
Fig. 3 shows the formulation with the greatest URDD rate of abuse
and diversion in each state, using the same methods as the primary
analysis for each program. Consistent with the nationwide data, in the
Poison Center and Drug Diversion Programs, abuse and diversion rates
of combination tablets exceeded that of other formulations in most
states, while in the treatment and College Survey Programs, abuse of
single ingredient tablets was most common in most states. Combi-
nation ﬁlm rates exceeded those of other formulations in one state in
the Poison Center Program (Mississippi), in two states in the College
Survey Program (Indiana, Virginia), and in no states in the Drug
Diversion Program or the treatment programs. No regional pattern
was apparent.
4. Discussion
4.1. Comparison to previous published literature
The introduction of ofﬁce-based treatment with buprenorphine
has greatly expanded access to treatment for opioid dependence in
the US, and the effectiveness of buprenorphine-based therapy has
been well-established. These results show that all three sublingual
buprenorphine formulations sold in the US are sometimes diverted for
illegal sale and abused. However, abuse and diversion rates varied
widely between formulations. The sublingual ﬁlm combination
product had lower abuse and diversion rates than either tablet
formulation in all programs. The reasons for these relative priorities
are not clear, but the relationships are statistically robust and have
remained consistent over at least 2 years of observation in each
program. Interestingly, the combination tablets consistently resulted
in the greatest rates of calls to poison centers and drug diversioninvestigations, while single ingredient tablets were responsible for
greater abuse rates among patients entering substance abuse therapy
and college students.
Buprenorphine tablet abuse and diversion has been described in the
US and internationally, and is common in some settings (Strang, 1985;
Yokell et al., 2011). One study reported that up to 20% of buprenorphine
patients in France misused their prescription by intravenous adminis-
tration (Auriacombe, Fatseas, Dubernet, Daulouede, & Tignol, 2004).
From 2002–2008, the number of patients entering treatment for
buprenorphine abuse at a large Finnish treatment center greatly
exceeded the number of patients entering treatment for heroin abuse,
with 83 percent of buprenorphine clients using their drug by injection
(Uosukainen et al., 2013). Previous research from the US has shown
that URDD rates of diversion and abuse of buprenorphine overall
increased from 2003–2007 (Dasgupta et al., 2010).
Although direct comparison between drugs prescribed for anal-
gesia and drugs prescribed to treat opioid dependence is problematic,
some context is useful. In this study, availability-adjusted rates of
buprenorphine abuse and diversion were often greater than recently
reported abuse and diversion rates of opioid analgesics and
methadone (Dart et al., 2012; Dasgupta et al., 2010; Severtson et al.,
2013). During time period of the current study, RADARS System
program event rates for buprenorphine sublingual formulations
generally exceeded those of oxycodone immediate release products,
probably because of the large population of patients who receive
short-duration prescriptions for oxycodone and who are at very low
risk for abuse. Conversely, hydromorphone abuse and diversion rates
often exceeded buprenorphine rates. Unfortunately, a direct compar-
ison the other opioid commonly used to treat opioid dependence,
liquid methadone, is not possible because a large proportion of
methadone is dispensed through federally-licensed opioid treatment
programs and therefore not captured in our dispensing (URDD) data.4.2. Limitations of this study
Measuring behavior that the person is actively trying to conceal is
an imperfect process, and these results are subject to several
additional limitations.
Drug Diversion Program data cannot determine the motivation of the
ultimate customer of diverted buprenorphine. Illicit self-administration of
buprenorphine to treat opioid dependence, reduce withdrawal
symptoms, decrease the illicit use of other opioids, and decrease
injection drug use have all been well-described (Hakansson,
Medvedeo, Andersson, & Berglund, 2007; Monte, Mandell, Wilford,
Buprenorphine tablets
Buprenorphine / naloxone tablets
Buprenorphine / naloxone film
No sublingual buprenorphine cases in program during time period
No program coverage during time period
Poison Center Program
Intentional Abuse Cases
Oct 2010–Dec 2012 
Drug Diversion Program
Illicit Diversion Investigations
Oct 2010–Dec 2012 
Treatment Programs
Abuse in the Past Month
April 2011–Dec 2012
College Survey Program
Non-Medicinal Use in the Past Semester 
Spring 2011– Fall 2012 
Shading denotes the formulation with the highest abuse, 
diversion, or non-medicinal use rate in that state
Fig. 3. Buprenorphine sublingual formulation with greatest average abuse and diversion rates in the RADARS® System, adjusted for drug availability, by state. Shading denotes the
formulation with the highest rate.
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proportion of users of illicitly-obtained buprenorphine who seek
euphoria, as opposed to self-medication, is tremendously variable
internationally, and has not been established in the US (Yokell et al.,
2011). Although the question administered in the OTP and SKIP
surveys (“used in [the] past month to get high”) is explicit and
designed to exclude self-medication, it is possible that some patients
do not understand the instructions. The treatment program abuse
rates do not distinguish between one-time and more frequent abuse
of an opioid during the month prior to entering therapy, and the
survey administered to all subjects collects only limited data about
route of administration. Although structured qualitative interview
research is being done in this population, to date these efforts have
not focused on buprenorphine abuse (Cicero, Ellis, & Surratt, 2012).
In addition, patients entering treatment may differ systematically
from the larger population of prescription opioid abusers. Abuse and
diversion rates may change as the ﬁlm formulation becomes further
established, a phenomenon that was observed for buprenorphine
tablet formulations (Cicero, Surratt, & Inciardi, 2007).4.3. Future research directions
There are several explanations for the observed differences that
cannot be evaluated with these data and represent opportunities for
future research.4.3.1. Route of administration and other techniques associated with
buprenorphine abuse
It is unclear whether buprenorphine tablet formulations can be
manipulated for parenteral administration in a way that provides
more euphoria (“a better high”) than the ﬁlm formulation. If correct,
this could be due to intrinsic advantages of the ﬁlm formulation or due
to longer access to and experience with the tablets. Quantitative data
about routes of abuse and qualitative data garnered from interviews
with buprenorphine abusers entering treatment may provide an
explanation. Structured surveillance of common Internet forums
devoted to illicit drug use shows that buprenorphine abusers prefer
the tablets because they perceive the ﬁlm formulation as “weak,” from
a euphoria perspective. Focused investigations to understand speciﬁc
features that make the ﬁlm formulation less desired by abusers may
lead to improved abuse-deterrent technology.
4.3.2. Diversion-deterrent packaging
Each combination ﬁlm packet has a unique randomly numbered
bar code; with future implementation of technology, this may
eventually allow law enforcement agencies to identify the source of
diverted medication. To our knowledge, the effectiveness of diver-
sion-deterrent packaging has not been studied.
4.3.3. Dose and formulation
This study did not attempt to determine the rate of abuse and
diversion of different strengths of each buprenorphine formulation.
33E.J. Lavonas et al. / Journal of Substance Abuse Treatment 47 (2014) 27–34Although a top-level analysis shows that the vast majority (84–90%)
of patients ﬁlling prescriptions for each formulation obtained the
8 mg strength, it is possible that a detailed analysis of dose and
formulation may yield additional insights.
4.3.4. Changing rates over time
Although this study was not designed to evaluate trends over time,
abuse of the combination tablets and diversion of both single
ingredient and combination tablets appeared to be increasing during
the study period. Several subsequent major policy changes have
occurred. The authorization of buprenorphine dispensing through
opioid treatment programs (January 2013), introduction of generic
combination tablets (February 2013), and introduction of mental
health parity and formulary requirements in the Affordable Care Act
(January 2014) will all lead to expanded access to buprenorphine
therapy and may increase diversion and abuse. Close surveillance is
needed to understand the societal impact of these changes.
4.4. Conclusion
Rates of abuse and diversion of buprenorphine tablets, with or
without naloxone, consistently exceed those of buprenorphine/
naloxone combination ﬁlm.
Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jsat.2014.02.003.
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